What is nutrigenomics?

Nutrigenomics is the science of how your genes interact with the food you eat. Specific variants in your DNA change how you metabolise caffeine, process saturated fat, absorb vitamin D, respond to sodium, and convert plant nutrients into usable forms. A nutrigenomic test reads those variants and translates them into evidence-based dietary recommendations - so instead of following generic guidelines, you eat in a way that matches your biology.

If you've already done a blood panel and found yourself staring at "in-range" results while still feeling tired, bloated, or stuck on a plateau, you're hitting the wall that bloods alone can't get past. Blood tests tell you what's happening right now. Your genes tell you why - and what's likely to keep happening unless you change something upstream.

This guide explains what nutrigenomics is (and isn't), walks through the gene-diet interactions with the strongest scientific evidence, and shows you how to combine genetic data with regular bloodwork to build a diet that's truly personalised.

Want to see your own gene-diet interactions? The FitnessGenes DNA Analysis decodes over 1000s of nutrition-related variants and pairs them with personalised food, supplement, and macro recommendations.

How does nutrigenomics actually work?

Every cell in your body runs on instructions written in DNA. About 99.9% of that code is identical between any two humans - but the 0.1% that varies is what makes you metabolically distinct from the person next to you in the gym.

Most of those differences come down to single-nucleotide polymorphisms, or SNPs (pronounced "snips"). A SNP is a single-letter swap in the genetic code at a specific location. One letter doesn't sound like much, but if that letter sits inside a gene that codes for an enzyme - say, the one that clears caffeine from your bloodstream - the swap can make that enzyme work twice as fast, or half as fast, as the standard version.

Nutrigenomics studies these SNPs in the context of diet. Researchers look at large populations, identify which variants correlate with which nutritional outcomes, and then run controlled trials to confirm the effect. The result is a growing catalogue of gene-diet interactions where we can say, with reasonable confidence, people with variant X respond differently to nutrient Y.
‍

Which gene-diet interactions are actually well-evidenced?

Not every nutrigenomic claim deserves equal weight. The science ranges from rock-solid (replicated in dozens of studies across multiple ethnicities) to "interesting preliminary signal." Here are the interactions with the strongest evidence base.
‍

CYP1A2 and caffeine metabolism

The CYP1A2 gene codes for the liver enzyme that clears around 95% of the caffeine you consume. A SNP at position rs762551 splits the population into two functional groups: fast metabolisers (AA genotype) and slow metabolisers (AC or CC genotypes).

For fast metabolisers, caffeine clears the bloodstream quickly. Moderate intake is associated with reduced risk of hypertension and even better athletic performance. For slow metabolisers, the same dose lingers for hours, and the evidence suggests that more than two cups of coffee per day is associated with elevated risk of hypertension, slower reaction times, and - in some studies - a higher risk of non-fatal heart attacks in adults under 50.

This is one of the most reproducible findings in nutrigenomics, confirmed in cohorts across Europe, North America, and Asia. If you're a slow metaboliser, drinking four espressos a day and wondering why your sleep is wrecked, your genes have an answer your Fitbit can't give you.
‍

APOE and saturated fat

The APOE gene comes in three common variants: ε2, ε3, and ε4. You inherit one from each parent, so possible combinations include ε3/ε3 (most common), ε3/ε4, ε4/ε4, and so on.

People carrying at least one ε4 allele show a notably stronger LDL cholesterol response to dietary saturated fat. In trials where ε4 carriers cut saturated fat intake, LDL drops more than it does in ε3/ε3 individuals on the same diet. The ε4 variant is also the best-established genetic risk factor for late-onset Alzheimer's disease, which has prompted decades of research into whether dietary intervention can modify that risk.

The practical takeaway: ε4 carriers tend to benefit from a Mediterranean-style pattern that's lower in saturated fat and higher in monounsaturated fats and omega-3s. ε3/ε3 individuals have more dietary flexibility - saturated fat moves their LDL less, though it still moves it.
‍

MTHFR and folate

The MTHFR gene produces an enzyme that converts dietary folate into its active form, methylfolate, which the body uses for DNA synthesis, neurotransmitter production, and homocysteine regulation. The C677T variant reduces enzyme activity by around 35% in heterozygotes (CT) and 70% in homozygotes (TT).

People with the TT genotype generally have higher homocysteine levels and lower circulating folate. The evidence-based response is to prioritise dietary folate from leafy greens, legumes, and liver, and, if supplementing, to choose methylfolate (5-MTHF) rather than synthetic folic acid, which must be converted by the same enzyme that is impaired.

MTHFR is also a good example of why context matters. Online communities have wildly overstated the variant's effects. It is not a "disease gene," and most people with TT genotypes are perfectly healthy. The intervention is dietary, not pharmaceutical.
‍

FTO and weight regulation

The FTO gene contains variants strongly associated with body mass index across populations. The AA genotype at rs9939609 is linked with an average BMI 1.2 kg/m² higher than the TT genotype and roughly a 1.6 times higher risk of obesity, though the effect appears to be mediated by appetite regulation rather than metabolic rate.

Interestingly, the FTO–obesity association is not destiny. Studies show that the effect of the risk variant is substantially reduced, and sometimes eliminated, in people who maintain high physical activity levels. This is one of the clearest demonstrations in nutrigenomics that genotype sets a tendency, not a verdict.

For AA carriers, the practical implications cluster around protein intake (which suppresses appetite more effectively), meal structure (regular eating patterns vs. grazing), and consistent activity.
‍

TCF7L2 and carbohydrate response

The TCF7L2 gene is the single strongest common genetic risk factor for type 2 diabetes identified to date. Variants at rs7903146 are associated with impaired insulin secretion and a stronger blood glucose response to high-glycaemic carbohydrates.

For carriers of the risk allele, a lower-glycaemic dietary pattern - emphasising whole grains, legumes, vegetables, and slower-digesting carbohydrate sources - produces better fasting glucose and HbA1c outcomes than a standard diet. This is one of the gene–diet interactions where modifying carbohydrate quality (not necessarily quantity) has a measurable downstream effect.
‍

VDR and vitamin D

Variants in the vitamin D receptor gene (VDR) affect how efficiently your cells respond to circulating vitamin D. Two people can have identical serum 25-hydroxyvitamin D levels on a blood test and yet have meaningfully different functional vitamin D status because their receptors handle the hormone differently.

This is one reason a "normal" vitamin D blood result doesn't always feel normal. Combined with variants in GC (which codes for vitamin D binding protein) and CYP2R1 (which activates vitamin D in the liver), VDR genotype helps explain why some people need higher intakes - from sunlight, oily fish, or supplements - to reach the same functional state.
‍

APOA2 and saturated fat–driven weight gain

The APOA2 gene codes for apolipoprotein A-II, the second most abundant protein in HDL particles. A variant at position rs5082 has produced one of the more striking gene–diet interactions in the literature: among people carrying the CC genotype, high saturated fat intake (above roughly 22g per day) is associated with significantly higher BMI and obesity risk. Carriers of the T allele show no such relationship - they can eat the same saturated fat load without the same weight effect.

The finding has been replicated across multiple independent cohorts in the US, Mediterranean, and Asian populations, which is the gold standard for a nutrigenomic interaction. Mechanistically, APOA2 appears to influence satiety signalling and food preference, with CC carriers showing stronger preferences for energy-dense foods - meaning the interaction is partly behavioural, not just metabolic.

This sits alongside APOE as one of the two best-evidenced reasons to think carefully about saturated fat intake on a genetic basis. The practical advice for CC carriers: keep saturated fat below the ~22g threshold and lean on monounsaturated fats (olive oil, nuts, avocado) instead.
‍

FADS1/FADS2 and omega-3 conversion

The FADS1 and FADS2 genes code for the delta-5 and delta-6 desaturase enzymes that convert plant-based omega-3 (ALA, from flaxseed, walnuts, chia) into the long-chain forms EPA and DHA that your brain, heart, and inflammatory pathways actually use. Variants in this gene cluster - particularly at rs174537 and rs174546 - have a large effect on conversion efficiency.

People with the "low-converter" genotype turn ALA into EPA/DHA at substantially reduced rates. For someone eating a plant-based or low-fish diet, this can mean chronically suboptimal omega-3 status despite adequate ALA intake on paper. Population data show the low-converter variants are more common in populations with historical fish-rich diets (Northern European), and the higher-converter variants are more common in populations with historically plant-based diets (parts of South Asia and Africa) - a textbook example of diet shaping the genome over millennia.

The practical implication is clear: if you're a low converter, plant sources of omega-3 alone are unlikely to get your EPA and DHA where they need to be. Either eat oily fish two to three times a week or supplement directly with EPA/DHA from fish or algal oil. High converters have more flexibility and can rely more on plant sources.

FADS variants also interact with vegetarian and vegan diets in ways that matter: the lower a converter you are, the more important direct DHA sources (or algal supplementation) become for maintaining brain and cardiovascular health markers.

Other well-evidenced interactions worth knowing

• ACE and sodium sensitivity - variants influence how blood pressure responds to dietary salt
• LCT and lactose tolerance - the textbook example; variants determine whether lactase persists into adulthood
• PPARG and unsaturated fats - affect insulin sensitivity in response to dietary fat composition‍
• HFE and iron absorption - variants affect iron uptake and risk of overload
  ‍

Is nutrigenomic testing actually useful, or is it hype?

Both, depending on what you're being sold.

The honest version of nutrigenomics has clear boundaries. Your genes are not a diet plan. They're one input - a stable, lifelong input that interacts with everything else: your training, sleep, stress, gut microbiome, age, and current biochemistry. A genuinely useful test interprets your variants in light of the published evidence, flags interactions with high confidence, and is transparent about interactions where the science is still evolving.

The hype version sells "your perfect diet from a cheek swab," claims to predict food sensitivities from SNPs (the evidence isn't there), or generates dramatically different meal plans from the same data depending on which company you send it to. That last point is worth taking seriously: in 2018, journalists submitted identical samples to multiple DTC genetic nutrition companies and received contradictory recommendations. The problem wasn't the DNA - it was inconsistent interpretation pipelines and overreach beyond the evidence.

What separates a useful test from a hype test:

• Variants chosen for the strength of their evidence base, not for marketing appeal
• Effect sizes communicated honestly - "you have a slightly elevated tendency to X" vs. "you must avoid Y"
• Interpretation that names the limitations of single-variant analysis
• Recommendations grounded in published intervention trials, not just association studies
  ‍

How should I combine genetic results with blood tests?

This is the question that separates people who get real value from personalisation from people who just have a lot of numbers.

Blood tests and DNA tests answer fundamentally different questions, and they're at their most powerful when you read them together.

Blood tests are a snapshot of your current biochemistry. Vitamin D, ferritin, fasting glucose, HbA1c, lipid panel, thyroid markers - these tell you what your body is doing today, after years of accumulated diet, lifestyle, and environment. They change in response to what you eat, drink, sleep, and train. They're how you verify that an intervention is working.

DNA tests are a map of your tendencies. They tell you which biochemical pathways are likely to drift in which direction if you don't actively manage them. They don't change.

Used together, the workflow looks something like this:

• Start with your DNA to understand which pathways need attention. If you're a MTHFR TT, VDR low-response, and APOE ε3/ε4, you already know where to look.
• Use bloodwork to measure the current state of those pathways. Homocysteine and folate for MTHFR. 25(OH)D for vitamin D pathway. Full lipid panel for APOE.
• Intervene specifically - methylfolate-rich foods for MTHFR; higher vitamin D intake or supplementation for VDR; reduced saturated fat for APOE ε4.
• Retest bloods in 3-6 months to verify the intervention is moving the needle.
• Iterate.

This is the closed loop that bloods alone - or DNA alone - can't give you. Bloods without genetic context tell you a number is off, but not why or where it'll drift next. DNA without bloods tells you what to watch but not whether your current strategy is working.
‍

What nutrigenomics can't do?

A short list of honest limitations, because they matter:

Single-variant nutrigenomic testing doesn't predict complex outcomes like long-term weight loss with high precision. It tells you about tendencies and pathways, not destinies. The most rigorous trial in this space - the DIETFITS study at Stanford - found that genotype patterns didn't predict whether participants lost more weight on a low-fat versus low-carb diet over 12 months. That doesn't invalidate nutrigenomics; it tells you that which diet works for weight loss is driven by adherence and many factors beyond a handful of SNPs. The gene-diet interactions that are robust tend to be biochemical (caffeine clearance, lipid response, vitamin metabolism) rather than behavioural.

Nutrigenomics also doesn't replace medical investigation. If you have symptoms - chronic fatigue, persistent GI issues, anything unexplained - see a doctor. A SNP report is not a substitute for clinical workup.
‍

The bottom line

Nutrigenomics is real science with real limits. The well-evidenced gene-diet interactions - CYP1A2 and caffeine, APOE and saturated fat, MTHFR and folate, FTO and appetite, TCF7L2 and carbohydrates, VDR and vitamin D - give you a level of dietary precision that no general guideline can match. The hype version of nutrigenomics overpromises a "perfect diet"; the honest version gives you a map of your tendencies and a starting point for smarter, evidence-based decisions.

Used in isolation, DNA tests are interesting but incomplete. Combined with regular bloodwork, they form a closed feedback loop: genes tell you where to look, bloods tell you what's happening, interventions move the needle, and follow-up bloods confirm what's working. That's how personalised nutrition stops being a buzzword and starts being a practice.

If you're already invested in tracking your health with services, adding a DNA layer is the logical next step. You'll stop guessing why your vitamin D won't budge, why coffee wrecks your sleep, or why your LDL responds to changes that don't affect your training partner.
‍

Author

Dr Stuart Grice, Chief Scientific Officer at FitnessGenes. A geneticist and former Oxford academic with a research background in genomics and disease, Dr Grice has spent his career translating biological data into actionable lifestyle protocols. The work that underpins FitnessGenes' US patent (US 10,621,499 B1) covers methods for generating personalised training and nutrition recommendations from genetic data.
‍

FAQS

What's the difference between nutrigenomics and nutrigenetics?

Nutrigenomics studies how nutrients influence gene expression - how food changes what your genes do. Nutrigenetics studies how your inherited DNA variants change your response to nutrients. In consumer testing, the terms are used interchangeably, and a good test draws from both fields.
‍

Is a DNA-based diet better than a standard healthy diet?

For most people, a standard healthy diet (Mediterranean-style, plenty of plants, adequate protein, minimal ultra-processed food) is already 80% of the answer. Nutrigenomics refines the remaining 20% - caffeine tolerance, saturated fat sensitivity, folate form, and vitamin D requirements - and is most useful for people who've already done the basics and want to go further.
‍

How accurate is at-home nutrigenomic testing?

The genotyping itself, done on a quality SNP array, is highly accurate (>99% for validated variants). The variation between companies comes from interpretation: which variants they test, how they weigh the evidence, and how they translate genotype into advice. Look for companies that disclose the variants tested and reference the underlying studies.
‍

Will my insurance see my genetic results?

In the UK, results from a private consumer DNA test are not shared with the NHS or insurers unless you choose to share them. In the US, GINA (the Genetic Information Nondiscrimination Act) prevents health insurers and employers from using genetic information against you, though it doesn't cover life or disability insurance. Always check the privacy policy of any company you submit a sample to.
‍

Do I need to retest my DNA?

No. Your DNA doesn't change. You take the test once. What evolves is the interpretation, as new gene-diet interactions are validated in the literature, a good testing service will update your report and recommendations without requiring a new sample.
‍

Can nutrigenomics help with weight loss?

Indirectly. It can identify variants that affect appetite regulation (FTO), carbohydrate response (TCF7L2), and fat metabolism (APOE, PPARG), and tailor macros accordingly. But the strongest predictor of weight loss is still adherence to a sustained calorie deficit. Nutrigenomics helps you find a deficit that's easier to stick to - not a shortcut around the maths.
‍

Is FitnessGenes different from 23andMe or Ancestry?

Yes. 23andMe and Ancestry test broad sets of variants primarily for ancestry and health risk reporting. FitnessGenes focuses specifically on fitness, nutrition, and performance variants, with recommendations developed by an in-house scientific team and a patented integration methodology. You can also upload existing raw data from 23andMe or AncestryDNA for interpretation by FitnessGenes.
‍

References

Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA. 2006;295(10):1135–1141.

Palatini P, Ceolotto G, Ragazzo F, et al. CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. Journal of Hypertension. 2009;27(8):1594–1601.

Bennet AM, Di Angelantonio E, Ye Z, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA. 2007;298(11):1300–1311.

Griffin BA, Walker CG, Jebb SA, et al. APOE4 genotype exerts greater benefit in lowering plasma cholesterol and apolipoprotein B than wild type (E3/E3), after replacement of dietary saturated fats with low glycaemic index carbohydrates. Nutrients. 2018;10(10):1524.

Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics. 1995;10(1):111–113.

Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826):889–894.

Kilpeläinen TO, Qi L, Brage S, et al. Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. PLOS Medicine. 2011;8(11):e1001116.

Grant SFA, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nature Genetics. 2006;38(3):320–323.

Cornelis MC, Qi L, Kraft P, Hu FB. TCF7L2, dietary carbohydrate, and risk of type 2 diabetes in US women. American Journal of Clinical Nutrition. 2009;89(4):1256–1262.

Uitterlinden AG, Fang Y, van Meurs JBJ, Pols HAP, van Leeuwen JPTM. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004;338(2):143–156.

Corella D, Peloso G, Arnett DK, et al. APOA2, dietary fat, and body mass index: replication of a gene-diet interaction in 3 independent populations. Archives of Internal Medicine. 2009;169(20):1897–1906.

Corella D, Tai ES, Sorlí JV, et al. Association between the APOA2 promoter polymorphism and body weight in Mediterranean and Asian populations: replication of a gene-saturated fat interaction. International Journal of Obesity. 2011;35(5):666–675.

Schaeffer L, Gohlke H, Müller M, et al. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Human Molecular Genetics. 2006;15(11):1745–1756.

Ameur A, Enroth S, Johansson Å, et al. Genetic adaptation of fatty-acid metabolism: a human-specific haplotype increasing the biosynthesis of long-chain omega-3 and omega-6 fatty acids. American Journal of Human Genetics. 2012;90(5):809–820.

Gardner CD, Trepanowski JF, Del Gobbo LC, et al. Effect of low-fat vs low-carbohydrate diet on 12-month weight loss in overweight adults and the association with genotype pattern or insulin secretion: the DIETFITS randomized clinical trial. JAMA. 2018;319(7):667–679.

Fenech M, El-Sohemy A, Cahill L, et al. Nutrigenetics and nutrigenomics: viewpoints on the current status and applications in nutrition research and practice. Journal of Nutrigenetics and Nutrigenomics. 2011;4(2):69–89.